{"id":"W2119967200","doi":"10.1007/s12032-011-0016-8","title":"Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement","year":2011,"lang":"en","type":"review","venue":"Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Hospital Foundation","funders":"Novartis Pharma; Sanofi; Bayer HealthCare; GlaxoSmithKline; Pfizer","keywords":"Sunitinib; Sorafenib; Temsirolimus; Everolimus; Medicine; Pazopanib; Renal cell carcinoma; Bevacizumab; Internal medicine; Oncology; Axitinib; Pharmacology; Hepatocellular carcinoma; Discovery and development of mTOR inhibitors; PI3K/AKT/mTOR pathway; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009368404,0.0004740483,0.002367609,0.0002468238,0.00004811965,0.000006504695,0.00031489,0.0002834384,0.001384922],"category_scores_gemma":[0.0002214441,0.0002364919,0.0003249803,0.0002754141,0.0003598971,0.00004898879,0.00006101861,0.0006232242,0.00002854543],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007644587,"about_ca_system_score_gemma":0.002915296,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003583124,"about_ca_topic_score_gemma":0.0002703579,"domain_scores_codex":[0.9954949,0.001379418,0.001305229,0.0005456799,0.0008370303,0.0004377167],"domain_scores_gemma":[0.9974048,0.0004195701,0.0006960916,0.0006691113,0.0001131115,0.0006973695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00227685,0.004305096,0.0009006242,0.009732557,0.0007308496,0.009713051,0.001268499,0.000002034162,0.00001404484,0.00007238181,0.001192486,0.9697915],"study_design_scores_gemma":[0.01148035,0.01016371,0.004228787,0.007249823,0.008092076,0.0005378001,0.0002687664,0.0002864483,0.00003214748,0.00003018389,0.957112,0.0005179414],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.004181596,0.990796,0.0003977262,0.0005891444,0.0001786205,0.002811564,0.0000255955,0.00001657182,0.001003152],"genre_scores_gemma":[0.08099221,0.9151758,0.0006683787,0.001123231,0.0002799974,0.0008969482,0.0005515711,0.00008226806,0.0002295786],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9692736,"threshold_uncertainty_score":0.9995279,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07924066159462474,"score_gpt":0.3525873089175282,"score_spread":0.2733466473229035,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}